ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Clinical trials for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot may simplify lung cancer treatment, phase 3 trial underway
Disease control OngoingThis study tests a new form of the drug amivantamab that can be given as a shot under the skin, combined with the pill lazertinib, for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after prior treatments. The goal …
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Lung cancer trial tests cocktail of new drugs against standard care
Disease control OngoingThis phase 2 study tests several new drug combinations in people with non-small-cell lung cancer. It includes three substudies: one for untreated advanced cancer, one for cancer that has progressed after prior treatment, and one for early-stage cancer that can be surgically remov…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pfizer drug shows promise against tough cancers
Disease control OngoingThis study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo aims to outperform chemo in tough lung cancers
Disease control OngoingThis study tests whether a new drug combination (ceralasertib plus durvalumab) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has stopped responding to prior treatments. About 594 participants will be randomly assigned…
Matched conditions: ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC